Polypill Strategy in Secondary Cardiovascular Prevention
Why the study?
Does a polypill containing aspirin, ramipril, and atorvastatin reduce major adverse cardiovascular events in patients within 6 months after myocardial infarction?
Population
Patients within 6 months after myocardial infarction
Comparison
Polypill containing aspirin, ramipril, and atorvastatin vs usual care
Authors
Discussion
Loading...
Member takes
Implication
Supports polypill use for post-MI secondary prevention; extends evidence for fixed-dose combinations in high-risk patients.
Structured PICO
Does a polypill containing aspirin, ramipril, and atorvastatin reduce major adverse cardiovascular events in patients within 6 months after myocardial infarction?
P
Population
Patients within 6 months after myocardial infarction
I
Intervention
Polypill containing aspirin, ramipril, and atorvastatin
C
Comparator
Usual care
O
Outcome
Major adverse cardiovascular eventscomposite
A polypill strategy containing aspirin, ramipril, and atorvastatin significantly reduces the risk of major adverse cardiovascular events compared to usual care in secondary prevention post-myocardial infarction.
Cite This Study
Castellano et al. (2022) studied this question.